TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock Now Rated “Hold” by Sell-Side Analysts

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $10.20.

A number of equities analysts have recently issued reports on TLSI shares. Guggenheim set a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Wednesday, September 23rd. HC Wainwright boosted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Finally, Zacks Research raised TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th.

TriSalus Life Sciences Trading Up 3.4%

NASDAQ TLSI opened at $3.93 on Thursday. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. The company has a market capitalization of $241.99 million, a price-to-earnings ratio of -3.02 and a beta of 0.47. The company’s 50-day simple moving average is $4.50 and its two-hundred day simple moving average is $4.44. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $11.41 million during the quarter, compared to the consensus estimate of $10.27 million. Equities analysts forecast that TriSalus Life Sciences will post -0.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Cura Wealth Advisors LLC bought a new stake in TriSalus Life Sciences during the second quarter valued at about $36,000. Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences in the first quarter valued at about $124,000. Deutsche Bank AG purchased a new position in TriSalus Life Sciences in the second quarter valued at about $221,000. Sei Investments Co. purchased a new position in TriSalus Life Sciences in the first quarter valued at about $275,000. Finally, CWA Asset Management Group LLC purchased a new position in TriSalus Life Sciences in the third quarter valued at about $310,000. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.